IART (Integra) Market Value to Book Value Ratio

Integra (IART) - corporate logo

Integra LifeSciences (IART) is reducing industrial emissions and energy consumption by implementing eco-friendly packaging standards and ethical sourcing. Simultaneously, the business is transitioning to automated production lines for collagen matrices in sterile zones, where the 0.88 metric determines the trend. Serving as the primary valuation tool, this price chart illustrates the share value of the regenerative therapy leader, whose brand is highly regarded by neurosurgeons for its flawless bioimplants.

Market Capitalization to Net Assets: Integra LifeSciences Inc. (IART) for 07/04/2022 - 10/27/2026
Finished products of Integra LifeSciences Corp

This indicator compares the current market value of Integra LifeSciences (IART) with its net assets, measuring the premium investors place on the business's tangible base. Stable demand for neurosurgical instruments and regenerative materials supports the capitalization, making the market-to-book ratio an indicator of cash flow stability and the company's ability to maintain its market premium.

Direct competitors

BSX - Market Cap to Net Assets Ratio|EW (edwards.com) - Market Cap to Book Value Multiple|RMD: Market Value to Book Value Ratio|Market Capitalization to Book Value PODD|ZBH - Market Value to Book Value Ratio|Market Capitalization to Net Assets CooperSurgical (COO)|ALGN: Market Capitalization to Book Value Ratio|Market-to-Book Ratio globusmedical.com GMED|TMDX: Market Capitalization to Book Value Ratio|ATEC - Market Cap to Net Assets Ratio|Artivion Inc - Market Capitalization to Book Value Ratio|Enovis Inc. (ENOV) - Market Capitalization to Book Value|ESTA (Establishment Labs) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio BBNX|Market Value to Book Value Ratio IRADIMED (IRMD)|Market Value to Book Value Ratio Embecta Corp (EMBC)|Market Capitalization to Book Value Ratio TNDM|AXGN - Market Capitalization to Book Value|Market Cap to Net Assets Ratio SI-BONE, Inc.|OFIX - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio BVS|OrthoPediatrics (KIDS) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Treace Medical (TMCI)|Capitalization to Book Value Ratio Strata Medical (SRTA)|Carlsmed Inc (CARL) - Market Cap to Net Assets Ratio|Market Value to Book Value RXST (rxsight.com)|ClearPoint Neuro - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Stereotaxis Inc STXS|STIM (NeuroStar) - Market Capitalization to Book Value Ratio|SGHT - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Orchestra BioMed|Anika Therapeutics, Inc. (ANIK) - Capitalization to Book Value Ratio|NSPR: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Jin Medical International Ltd|Market Capitalization to Book Value Ratio VANI (Vivani Medical, Inc.)|Market Cap to Net Assets Ratio xtantmedical.com (XTNT)|Market Capitalization to Book Value Ratio NMTC (NeuroOne Medical Technologies)|Modular Medical Inc - Market Capitalization to Book Value Ratio|MYO - Market Value to Book Value Ratio|Envoy Medical Inc. (COCH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Vivos Therapeutics, Inc VVOS|enVVeno Corp (NVNO) - Market Value to Book Value|Market Capitalization to Book Value Ratio SINT (Sintx Technologies Inc)|Market-to-Book Ratio TNON|LFWD: Market Value to Book Value Ratio|Market Value to Equity Ratio autonomix.com AMIX|Market Cap to Net Assets Ratio IVF (INVO Bioscience, Inc.)|Market Capitalization to Book Value Ratio Bone Biologics Inc BBLG|Market Capitalization to Book Value Ratio AXNX (Axonics, Inc.)|BIOL: Market Capitalization to Book Value|Market Value to Book Value Ratio dynatronics.com (DYNT)|FNA (Paragon 28) - Market Capitalization to Net Assets|Market Value to Book Value Ratio INVO